Monthly research recap
Depression research: June 2026
What June 2026's 25 new studies found, synthesized from the papers below. All Depression research →
The synthesis
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Depression, major depressive disorder, MDD, depressive disorder, treatment-resistant depression, then ranked by relevance.
Research published in June 2026 indicates that both mindfulness-based interventions and rapid-acting antidepressants (ketamine, esketamine, psilocybin) show promise for depression, with mindfulness consistently reducing symptoms and psychedelics/ketamine providing rapid relief, especially in treatment-resistant cases. However, evidence is mixed regarding long-term durability, and many studies are limited by small samples, lack of blinding, or short follow-up periods.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Mindfulness training accelerates anxiety and depression relief via enhanced psychological resilience 2026 | RCT | 133 | Supports | Mindfulness training significantly reduced anxiety and depression symptoms compared to control, with psychological resilience partially mediating these improvements. |
| Ketamine renaissance: Expanding horizons from anesthesia to depression and pain 2026 | review | Supports | Ketamine offers rapid antidepressant effects in treatment-resistant depression and efficacy in pain, but long-term safety and protocol standardization remain unresolved. | |
| Chronic psilocin microdosing produces limited behavioral effects and does not enhance neurogenesis in rats. 2026 | preclinical experimental study | No effect | Chronic psilocin microdosing did not affect depressive-like behavior, sociability, or neurogenesis, though a small anxiogenic effect was observed. | |
| Psychotherapy and Ketamine: How Does This Combination Affect the Duration of the Antidepressant Effect? 2026 | review | Mixed | Psychotherapy combined with ketamine may moderately prolong antidepressant effects, but data are heterogeneous and one study showed no advantage over ketamine monotherapy. | |
| Prevalence of Stress, Anxiety, and Depression and the Effectiveness of a Mindfulness-Based Life Coaching Intervention among 4th-Year Medical Students: A Pilot Quasi- Experimental Study 2026 | cross-sectional screening followed by single-arm pre-post intervention | 100 | Supports | A 21-day mindfulness-based life coaching program was associated with significant reductions in stress, anxiety, and depression among medical students with mild-to-moderate distress. |
| Psychedelics in treatment-resistant depression: a comprehensive review of mechanisms, clinical evidence, and recommendations. 2026 | review | Supports | Psychedelics, particularly psilocybin, ketamine, esketamine, and ayahuasca, show promise for treatment-resistant depression through mechanisms including neuroplasticity and corticolimbic enhancement. | |
| Esketamine multi-omic biomarker evaluation in major depressive disorder (EMBER-MDD): concept, objectives and methodologies of a non-clinical investigator-initiated study. 2026 | non-interventional, investigator-initiated, in-vitro study | 420 | Unclear | This study aims to discover biomarkers associated with treatment resistance risk and molecular correlates of clinical response to esketamine nasal spray versus treatment as usual. |
| Comprehensive Systematic Review of Esketamine Nasal Spray as a Standalone Rapid-Acting Treatment for Treatment-Resistant Depression: Integrating Clinical Trial Data and Emerging Real-World Evidence on Efficacy, Safety, And Relapse Prevention 2026 | review | Supports | Esketamine reduces depressive symptoms more effectively than placebo or quetiapine, with rapid onset and mild-to-moderate side effects. | |
| Intrinsic excitation-inhibition imbalance in major depressive disorder. 2026 | observational cohort with transcriptomic and neurochemical decoding, plus a clinical trial component | 254 | Supports | Patients with MDD showed reduced cortical excitation-inhibition balance, and ketamine increased this balance in treatment-resistant depression. |
| Evaluating the Impact of Transcendental Meditation on Trauma Symptoms, Depression, Anxiety, and Sleep Problems Among Israeli Civilians Post-October 7, 2023: A Pilot Study. 2026 | pilot study | 39 | Supports | Participation in transcendental meditation was associated with statistically significant decreases in PTSD symptoms, depression, anxiety, and sleep problems among trauma-exposed civilians. |
| Vaporized mebufotenin leads to improvement in treatment‐resistant depression 2026 | RCT | Supports | An individualized one-day dosing regimen of vaporized 5-MeO-DMT was more effective than placebo in improving depressive symptoms in adults with treatment-resistant depression. | |
| Rapid clinical improvement after intravenous ketamine in an adolescent with treatment-resistant depression, severe obesity, and pseudo-Cushing syndrome: A case report. 2026 | case report | 1 | Supports | A single intravenous ketamine infusion led to rapid and sustained improvement in depressive symptoms in an adolescent with treatment-resistant depression and multiple medical comorbidities. |
| Intranasal esketamine use in treatment-resistant depression: mechanism of action, clinical adverse effects, contraindications, safe administration protocol and treatment process 2026 | review | Supports | Esketamine provides a novel therapeutic approach for depression by targeting NMDA receptors and intracellular signaling pathways, with a need for careful administration due to adverse effects and contraindications. | |
| Unraveling the mediating role of anxiety and depression: Cultivating mindfulness to improve quality of life in Parkinson's disease patients. 2026 | secondary analysis of baseline data from a clinical trial | 159 | Supports | Higher mindfulness levels were associated with reduced anxiety and depression and improved health-related quality of life, with anxiety and depression mediating these associations. |
| Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram 2026 | observational cohort with pre- and post-treatment brain imaging | Mixed | Global brain network reconfiguration under perturbation increases after psilocybin and decreases after escitalopram treatment, suggesting distinct neural changes following each treatment. | |
| Dextromethorphan-bupropion-associated pharmacovigilance signals based on the FAERS database: An observational study. 2026 | observational pharmacovigilance study using FDA adverse event reporting system data | 3580 | Opposes | Dextromethorphan-bupropion is associated with adverse event signals, including psychiatric and nervous system disorders, with 65.3% of signals not listed in the drug's label. |
| Digital and In-Person Mindfulness-Based Interventions for University Students' Mental Health: A Systematic Review of Randomized Controlled Trials. 2026 | systematic review | 24 | Supports | Mindfulness-based interventions consistently reduce depression and generally improve anxiety among university students, with digital delivery showing comparable effectiveness to in-person formats. |
| Novel approaches in depression treatment: from rapid-acting antidepressants to personalized interventions. 2026 | review | Supports | Psilocybin has advanced to late-stage trials, and the SAINT protocol is FDA-cleared for treatment-resistant depression, while ongoing research explores EEG biomarker-guided and genetically guided personalized treatments. | |
| Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants. 2026 | randomized, double-blind, placebo-controlled, double-dummy, four-way cross-over study | 16 | Opposes | Oral S-ketamine has poor bioavailability and produces limited central nervous system effects compared to intravenous administration, with the lower oral dose lacking any effects. |
| Sex- and Age-Stratified Differences in Antidepressant Response to Intranasal Esketamine in Treatment-Resistant Depression: A Secondary Analysis of the REAL-ESK Study 2026 | secondary analysis of a prospective cohort study | 210 | Mixed | Intranasal esketamine was associated with substantial antidepressant improvement, and men showed a modest overall advantage in depression outcomes compared to women, though age-stratified sex differences were not statistically significant after correction. |
| THE IMPACT OF INTRANASAL ESKETAMINE ON TREATMENT-RESISTANT DEPRESSION: A SYSTEMATIC REVIEW 2026 | systematic review | Supports | Intranasal esketamine is associated with greater symptom improvement and higher response rates than control in TRD, but with more frequent adverse events such as dizziness and nausea. | |
| COMPARING ROUTES OF KETAMINE ADMINISTRATION IN TREATMENT-RESISTANT DEPRESSION: EFFICACY, SAFETY, AND OPTIMIZATION OF DOSING STRATEGIES 2026 | narrative review | Supports | Intravenous and intranasal routes are the best-supported options for rapid antidepressant response in treatment-resistant depression, while oral and sublingual forms may be useful for maintenance in resource-limited settings. | |
| PSILOCYBIN IN THE TREATMENT OF DEPRESSIVE DISORDERS: CLINICAL EVIDENCE AND ITS POTENTIAL TO ADDRESS THE GLOBAL MENTAL HEALTH CRISIS - A REVIEW 2026 | review | Supports | Psilocybin-assisted therapy offers rapid and lasting antidepressant effects for major depressive disorder and treatment-resistant depression, with symptom reduction often within the first week and benefits persisting 6–12 months. | |
| Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim test 2026 | experimental study | Supports | 5-HT2B receptors are required for psilocybin's rapid and sustained antidepressant-like behavioral effects in the forced swim test but not for its head-twitch response. | |
| Changes in hierarchical brain dynamics of rumination following mindfulness-based cognitive therapy for depression 2026 | RCT | 80 | Supports | MBCT plus treatment as usual increased brain hierarchy during rumination, and this increase was related to clinical and behavioral improvements. |
Points of agreement
- Mindfulness-based interventions consistently reduce depressive symptoms across diverse populations, including patients with anxiety/depression, medical students, university students, and Parkinson's disease patients.
- Ketamine and esketamine are effective rapid-acting antidepressants for treatment-resistant depression, with multiple reviews and trials supporting their efficacy.
- Psilocybin-assisted therapy shows rapid and sustained antidepressant effects in major depressive disorder and treatment-resistant depression.
- Psychedelics and ketamine may work through neuroplasticity and modulation of brain network dynamics.
Conflicts
- One study found that chronic psilocin microdosing had no effect on depressive-like behavior in rats, contrasting with the positive findings for full-dose psychedelics.
- Oral S-ketamine showed poor bioavailability and limited CNS effects, conflicting with the efficacy of intravenous and intranasal routes.
- A pharmacovigilance study identified adverse event signals for dextromethorphan-bupropion, including psychiatric disorders, which may temper its perceived benefit.
- Sex differences in esketamine response were found in one study but not consistently across age groups.
Gaps
- Long-term durability of antidepressant effects beyond 12 months is not well established for esketamine and other rapid-acting treatments.
- Most psychedelic trials have small sample sizes and lack adequate blinding, limiting the strength of conclusions.
- Optimal dosing and protocol standardization for ketamine and esketamine across routes remain unresolved.
- The role of specific receptor subtypes (e.g., 5-HT2B) in psilocybin's antidepressant effects needs further clinical validation.
- Biomarker-guided personalized treatments are still in early stages, with limited evidence for clinical implementation.